On February 11, 2026 SOFIE Biosciences, an established U.S. manufacturer and developer of radiopharmaceuticals, reported that the first patient has been dosed in the second of its two Phase 3 clinical trials evaluating [18F]FAPI-74, a fluorine-18 labeled radiopharmaceutical targeting Fibroblast Activation Protein (FAP), as a novel diagnostic for patients with Pancreatic Ductal Adenocarcinoma.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Dosing the first patient in our FAPI-PRO trial is a major step forward in the evaluation of FAPI as an oncological diagnostic tool," said Philipp Czernin, Chief Business Officer, SOFIE Biosciences. "We undergo this trial encouraged by the results of our Phase 2 and independent academic investigator-initiated studies supporting [18F]FAPI-74’s potential role in staging accuracy, which is especially needed for pancreatic cancer."
"The potential sensitivity of [18F]FAPI-74 PET makes its availability to stage patients with newly diagnosed pancreatic ductal adenocarcinoma attractive to patients and clinicians alike. The whole team, including surgeons and oncologists, are enthusiastic about using [18F]FAPI-74 PET to help select the best initial treatments," said Dr. Gary Ulaner, James & Pamela Muzzy Endowed Chair in Molecular Imaging and Therapy, Hoag Family Cancer Institute, and Professor of Radiology and Cancer Biology, University of Southern California.
The FAPI-PRO (FAPI in Precision Imaging of Pancreatic Cancer) trial is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of [¹⁸F]FAPI-74 PET/CT in the detection of metastatic disease in adults with Pancreatic Ductal Adenocarcinoma. The study is planned for 18 sites with an estimated enrollment of 200 subjects over a 24-month period.
The primary study endpoints are sensitivity and specificity for detection of distant metastatic disease (M1). For additional trial details, visit the study page on ClinicalTrials.gov NCT07217717).
The partner Phase 3 study, FAPI-GO (FAPI in Gastroesophageal Oncology), which began November 2025, is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of [¹⁸F]FAPI-74 PET/CT in the detection of metastatic disease in adults with gastroesophageal cancers. The first patient in FAPI-GO was dosed on December 26, 2025. For additional trial details, visit the study page on ClinicalTrials.gov (NCT07217704).
ABOUT [18F]FAPI-74
[18F]FAPI-74 is the lead fluorine-18 radiolabeled PET tracer in the FAPI family of compounds. It has demonstrated favorable dosimetry, avidity, safety, and a biodistribution profile amenable to detection of FAP-expressing cells in patients with various cancers. This radioligand for imaging is currently optimized for production within SOFIE and its clinical trial partners.
(Press release, Sofie Biosciences, FEB 11, 2026, View Source [SID1234662608])